Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Neurology Diabetes / Metabolic Rheumatology Gastroenterology Mental Health / Psychiatry Women's Health Dermatology Men's Health Rare Diseases
Clinical Trial ● Currently Recruiting NCT05008081

The CATALINA Study

The CATALINA Study — Recruiting • Respiratory / COPD / Asthma • NCT05008081.

📅 22 May 2026 ⏱ 1 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
NCT ID
NCT05008081
Sponsor
Wim Janssens
Start
2022-10-25
ClinicaliQ Trial Snapshot
  • The CATALINA Study — Recruiting • Respiratory / COPD / Asthma • NCT05008081.
  • Sponsor: Wim Janssens.

Verify eligibility, endpoints and current status on the original source registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

The CATALINA study is a prospective cohort study embedded within CICERO (Collaboration In COPD ExaceRbatiOns, a European Respiratory Society supported Clinical Research Collaboration), designed to collect standardised, longitudinal clinical data and biological samples in 20 centres across Europe and beyond.

Eligibility Snapshot
  • : * Age 18 years and older * Established diagnosis of COPD by medical doctor (based on clinical history OR pulmonary function test with an FEV1/FVC < 0.7) * Current hospitalization with suspicion of an acute exacerbation of COPD (AECOPD) * Inclusion within 48 hours post hospital admission * Voluntary written informed consent of the participant or his/her representative obtained prior to any study procedure

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Clinical Brief
‘I gave up my job due to the stress of my child’s food allergies’
Respiratory / COPD / Asthma · BBC Health · 23 Apr 2026
Parental burden of food allergies: Severe childhood food allergies can create such significant psychological stress that parents may feel compelled to leave…
View brief →
Clinical Brief
‘My baby scratches and scratches’: Families say their homes are making their children sick
Respiratory / COPD / Asthma · BBC Health · 23 Apr 2026
Temporary housing conditions are contributing to increased rates of childhood skin conditions (notably atopic dermatitis), with families reporting persistent scratching and distress…
View brief →
Clinical Brief
Rogue sperm donor who says he’s fathered 180 children won’t be on child’s birth certificate
Respiratory / COPD / Asthma · BBC Health · 21 Apr 2026
A rogue sperm donor case highlights the legal vulnerability of recipients using unregulated private donation arrangements, where donors may not be excluded…
View brief →
Guideline
2021 ESCMID Guidelines for the Management of Community-acquired Pneumonia
Respiratory / COPD / Asthma · 30 Mar 2026
This ESCMID guideline addresses 2021 ESCMID Guidelines for the Management of Community-acquired Pneumonia in Respiratory / COPD / Asthma. Use it to…
View guideline →
Clinical Brief
Cuba’s mothers-to-be prepare to give birth in a country plunged into darkness
Respiratory / COPD / Asthma · BBC Health · 24 Mar 2026
Two pregnant women tell the BBC's Will Grant of their hopes and fears as their nation is mired in crisis. This update…
View brief →
Clinical Brief
Short-acting beta 2 agonists (SABA) (salbutamol and terbutaline): reminder of the risks from overuse in asthma and to be aware of changes in the SABA prescribing guidelines
Respiratory / COPD / Asthma · MHRA · 24 Apr 2025
Healthcare professionals and patients are reminded of the risk of severe asthma attacks and increased mortality associated with overuse of SABA with…
View brief →